Advertisement

Midazolam oral solution (Ozalin®): a profile of its use for procedural sedation or premedication before anaesthesia in children

  • Katherine A. Lyseng-WilliamsonEmail author
Adis Drug Q&A
  • 8 Downloads

Abstract

Ozalin®, a novel oral solution of 0.2% midazolam, is an effective option for moderate sedation prior to a therapeutic or diagnostic procedure, and as premedication before anaesthesia, in infants, children and adolescents. Orally administered midazolam has a rapid onset and short duration of action, with well-established favourable efficacy, tolerability, safety and acceptability profiles in these indications. To overcome the problems of bitter taste and inconsistent bioavailability associated with extemporaneous formulations of oral midazolam, Ozalin, a commercially prepared oral midazolam formulation, contains the inert excipient γ-cyclodextrin, which forms inclusion complexes with midazolam, thereby enhancing the solubility and stability of midazolam solutions, and masking its bitter taste. Ozalin is administered at the lowest dose of midazolam (i.e. 0.25 mg/kg) that has been shown to be effective, with this dose providing sedative effects consistent with the historical data for midazolam at doses that were the same or higher (i.e. 0.5–1.5 mg/kg).

Notes

Acknowledgements

The manuscript was reviewed by: H. Dupont, Pôle Anesthésie-Réanimation, CHU Amiens-Picardie, and INSERM U1088, Amiens, France; F. Marçon, Pharmacie à Usage Intérieur, CHU Amiens-Picardie, Amiens, France; N. Najafi, Department of Anaesthesiology and Perioperative Medicine, Vrije Universiteit Brussel-Universitair Ziekenhuis Brussel, Brussels, Belgium; M. Vittinghoff, Department of Anesthesiology and Intensive Care, Medical University Graz, Graz, Austria. During the peer review process, Primex Pharmaceuticals, the marketing-authorization holder of Ozalin, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

K.A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

References

  1. 1.
    Ozalin 2 mg/ml oral solution: summary of product characteristics. Helsinki: Primex Pharmaceuticals OY; 2018.Google Scholar
  2. 2.
    Marçon F, Mathiron D, Pilard S, et al. Development and formulation of a 0.2% oral solution of midazolam containing γ-cyclodextrin. Int J Pharm. 2009;379(2):244–50.CrossRefGoogle Scholar
  3. 3.
    Mason KP, Seth N. Future of paediatric sedation: towards a unified goal of improving practice. Br J Anaesth. 2019.  https://doi.org/10.1016/j.bja.2019.01.025.Google Scholar
  4. 4.
    Zielinska M, Bartkowska-Sniatkowska A, Becke K, et al. Safe paediatric procedural sedation and analgesia by anaesthesiologists for elective procedures: a Clinical Practice Statement from the European Society for Pediatric Anaesthesiology. Paediatr Anaesth. 2019.  https://doi.org/10.1111/pan.13615.Google Scholar
  5. 5.
    Brosius KK, Bannister CF. Oral midazolam premedication in preadolescents and adolescents. Anesth Analg. 2002;94(1):31–6.Google Scholar
  6. 6.
    Neuman G, Swed Tobia R, Koren L, et al. Single dose oral midazolam for minor emergency department procedures in children: a retrospective cohort study. J Pain Res. 2018;11:319–24.CrossRefGoogle Scholar
  7. 7.
    Shoroghi M, Arbabi S, Farahbakhsh F, et al. Perioperative effects of oral midazolam premedication in children undergoing skin laser treatment: a double-blinded randomized placebo-controlled trial. Acta Cir Bras. 2011;26(4):303–9.CrossRefGoogle Scholar
  8. 8.
    Sarhan MM, Aldehayat GS. Preanesthetic medication using oral midazolam in children undergoing tonsillectomy under general anesthesia. Rawal Med J. 2011;36(4):237–68.Google Scholar
  9. 9.
    Sheta SA, Alsarheed M. Oral midazolam premedication for children undergoing general anaesthesia for dental care. Int J Pediatr. 2009;2009:274380.CrossRefGoogle Scholar
  10. 10.
    Khodadad A, Aflatoonian M, Jalilian R, et al. Comparison of oral midazolam with intravenous midazolam for sedation children during upper gastrointestinal endoscopy. Acta Med Iran. 2016;54(9):576–82.Google Scholar
  11. 11.
    Rafeey M, Ghojazadeh M. Oral midazolam in pediatric upper gastrointestinal endoscopy. J Gastroenterol Hepatol. 2012;5:104.Google Scholar
  12. 12.
    Aydintug YS, Okcu KM, Guner Y, et al. Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Mil Med. 2004;169(4):270–3.CrossRefGoogle Scholar
  13. 13.
    Deshmukh PV, Kulkarni SS, Parchandekar MK, et al. Comparison of preanesthetic sedation in pediatric patients with oral and intranasal midazolam. J Anaesth Clin Pharmacol. 2016;32(3):353–8.CrossRefGoogle Scholar
  14. 14.
    Manoj M, Satya Prakash MVS, Swaminathan S, et al. Comparison of ease of administration of intranasal midazolam spray and oral midazolam syrup by parents as premedication to children undergoing elective surgery. J Anesth. 2017;31(3):351–7.CrossRefGoogle Scholar
  15. 15.
    Gregory DF, Koestner JA, Tobias JD. Stability of midazolam prepared for oral administration. South Med J. 1993;86(7):771–772, 6.CrossRefGoogle Scholar
  16. 16.
    Steedman SL, Koonce JR, Wynn JE, et al. Stability of midazolam hydrochloride in a flavored, dye-free oral solution. Am J Hosp Pharm. 1992;49(3):615–98.Google Scholar
  17. 17.
    Isik B, Baygin O, Bodur H. Effect of drinks that are added as flavoring in oral midazolam premedication on sedation success. Paediatr Anaesth. 2008;18(6):494–500.CrossRefGoogle Scholar
  18. 18.
    Loftsson T, Gudmundsdóttir H, Sigurjónsdóttir JF, et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm. 2001;212:29–40.CrossRefGoogle Scholar
  19. 19.
    Jansook P, Ogawa N, Loftsson T. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int J Pharm. 2018;535(1–2):272–84.CrossRefGoogle Scholar
  20. 20.
    Mathiron D, Marcon F, Dubaele JM, et al. Benefits of methylated cyclodextrins in the development of midazolam pharmaceutical formulations. J Pharm Sci. 2013;102(7):2102–11.CrossRefGoogle Scholar
  21. 21.
    Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol. 1981;19(4):271–8.CrossRefGoogle Scholar
  22. 22.
    Guittet C, Manso M, Burton I, et al. A two-way randomized cross-over pharmacokinetic and pharmacodynamic study of an innovative oral solution of midazolam (ADV6209). Pharm Res. 2017;34(9):1840–8.CrossRefGoogle Scholar
  23. 23.
    Marçon F, Guittet C, Manso MA, et al. Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin. Eur J Pharm Sci. 2018;114:46–54.CrossRefGoogle Scholar
  24. 24.
    Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol. 1989;37(3):267–72.CrossRefGoogle Scholar
  25. 25.
    Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol. 2001;41(12):1359–69.CrossRefGoogle Scholar
  26. 26.
    Guittet C, Manso M, Granier LA. A phase I randomized two-way cross-over study comparing the pharmacokinetic profile and relative bioavailability of ADV6209 versus an extemporane oral midazolam formulation in healthy subjects [abstract no. 63 + poster]. In: European Society for Paediatric Anaesthesiology (ESPA) and Internationsl Assembly for Pediatric Anesthesis (IAPA) Congress. 2018.Google Scholar
  27. 27.
    Brill MJ, van Rongen A, Houwink AP, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet. 2014;53(10):931–41.CrossRefGoogle Scholar
  28. 28.
    Hohmann N, Kocheise F, Carls A, et al. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79(2):278–85.CrossRefGoogle Scholar
  29. 29.
    Lee JI, Chaves-Gnecco D, Amico JA, et al. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72(6):718–28.CrossRefGoogle Scholar
  30. 30.
    Tateishi T, Watanabe M, Nakura HY, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther. 2001;69(5):333–9.CrossRefGoogle Scholar
  31. 31.
    Goho C. Oral midazolam-grapefruit juice drug interaction. Pediatr Dent. 2001;23(4):365–6.Google Scholar
  32. 32.
    Guittet C, Manso M, Casagrande L, et al. Evaluation of the efficacy of an innovative oral formulation of midazolam for moderate sedation in pediatric patients [abstract no. PR240]. Anesth Analg. 2016;123 (3 Suppl 2):313–4.Google Scholar
  33. 33.
    Marçon F, Legrand A, Guittet C, et al. Phase II clinical study of a pediatric oral solution of midazolam 0.2% (Ozaline®) for anesthetic premedication [in French] [abstract no. R196]. In: Société Française d’Anesthésie et de Réanimation (SFAR). 2015.Google Scholar
  34. 34.
    Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990;10(4):244–51.CrossRefGoogle Scholar
  35. 35.
    Sadhasivam S, Ganesh A, Robison A, et al. Validation of the bispectral index monitor for measuring the depth of sedation in children. Anesth Analg. 2006;102:383–8.CrossRefGoogle Scholar
  36. 36.
    Malviya S, Voepel-Lewis T, Tait AR, et al. Depth of sedation in children undergoing computed tomography: validity and reliability of the University of Michigan Sedation Scale (UMSS). Br J Anaesth. 2002;88:241–5.CrossRefGoogle Scholar
  37. 37.
    Gonzalez Castro LN, Mehta JH, Brayanov JB, et al. Quantification of respiratory depression during pre-operative administration of midazolam using a non-invasive respiratory volume monitor. PLoS One. 2017;12(2):e0172750.  https://doi.org/10.1371/journal.pone.0172750.CrossRefGoogle Scholar
  38. 38.
    Prato FD, Knill RL. Diazepam sedation reduction functional residual capacity and alters the distribution of ventilation in man. Can Anaesth Soc J. 1983;30:493–500.CrossRefGoogle Scholar
  39. 39.
    von Ungern-Sternberg BS, Erb TO, Habre W, et al. The impact of oral premedication with midazolam on respiratory function in children. Anesth Analg. 2009;108(6):1771–6.CrossRefGoogle Scholar
  40. 40.
    Araki H, Fujiwara Y, Shimada Y. Effect of flumazenil on recovery from sevoflurane anesthesia in children premedicated with oral midazolam before undergoing herniorrhaphy with or without caudal analgesia. J Anesth. 2005;19(3):204–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations